KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Change in Accured Expenses (2016 - 2025)

Biogen (BIIB) has 17 years of Change in Accured Expenses data on record, last reported at $203.8 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 87.32% year-over-year to $203.8 million; the TTM value through Dec 2025 reached $171.1 million, up 595.53%, while the annual FY2025 figure was $171.1 million, 595.53% up from the prior year.
  • Change in Accured Expenses reached $203.8 million in Q4 2025 per BIIB's latest filing, down from $286.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.1 billion in Q2 2022 and bottomed at -$724.3 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is -$12.1 million, with a median of $14.8 million recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: plummeted 833.1% in 2022, then skyrocketed 24864.71% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $98.8 million in 2021, then tumbled by 833.1% to -$724.3 million in 2022, then soared by 31.59% to -$495.5 million in 2023, then skyrocketed by 121.96% to $108.8 million in 2024, then soared by 87.32% to $203.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $203.8 million in Q4 2025, $286.0 million in Q3 2025, and -$18.2 million in Q2 2025.